(Reuters) - Merck and Co Inc presented
trial results on Friday showing that a once-daily combination of
two experimental pills cured 95 percent of previously untreated
hepatitis C patients after 12 weeks.
The trial included patients infected with the most common
form of the liver-destroying virus, genotype 1, along with less
common genotypes 4 and 6. It also involved patients with and
without liver cirrhosis.
Cure rates, defined as sustained virologic response 12 weeks
after treatment, were 92 percent for patients with genotype 1a;
99 percent for genotype 1b; 100 percent for genotype 4; and 80
percent for genotype 6. Cures were achieved in 97 percent of
cirrhotic patients and 94 percent of non-cirrhotic patients.
Labels: grazoprevir/elbasvir, GT1, GT4, GT6, Merck